Introduction {#S0001}
============

Cancer is the leading cause of death globally.[@CIT0001] Chemotherapy, radiation therapy, and surgery are the main therapeutic approaches for cancer.[@CIT0001],[@CIT0002] The success of chemotherapy has been limited due to the lack of drug specificity to tumor cells, insufficient drug concentration in tumor cells, serious adverse effects, and the emergence of multidrug-resistant tumor cells.[@CIT0001]--[@CIT0003] Several strategies have been proposed to tackle these challenges facing conventional chemotherapeutic drugs, which includes the use of traditional or herbal medicines for cancer therapy. The use of herbal medicines for cancer therapy has been rising all over the world due to their biological activity as well as fewer adverse effects as compared to conventional chemotherapeutic drugs. Pharmacokinetics is the study of the relationship between the dose of a drug and its concentrations in the body fluids over time. This relationship is controlled mainly by the rate and extent of drug absorption, distribution, metabolism, and excretion processes, known as ADME. The critical pharmacokinetic parameters used to define these processes include bioavailability (F), elimination half-life (t~1/2~), volume of distribution (V~d~ or V~ss~), and clearance (CL) ([Figure 1](#F0001){ref-type="fig"}). Despite the impressive benefits of several herbal medicines, they exhibit some challenges such as poor pharmacokinetic profiles and the requirement of high doses which are commonly associated with toxicity.[@CIT0001] The goal of improving the pharmacokinetic profile of a drug is to obtain the desired therapeutic outcome with minimum toxicity.Figure 1Schematic diagram showing the four pharmacokinetic processes: absorption, distribution, metabolism and excretion (ADME) including their pharmacokinetic parameters.

Recently, the use of novel drug delivery systems such as nanoparticles has paved the way to the development of enhancing the pharmacokinetics of anticancer drugs.[@CIT0005]--[@CIT0009] Herb-derived active compounds or conventional chemical synthetic drugs incorporated with nanoparticles offer a solution to overcome their unsuitable pharmacokinetic properties, specificity, efficacy, and toxicity. Encapsulation of these compounds/drugs with nanoparticles would likely impact the pharmacokinetics and stability of the carried compounds. To our knowledge, the impact of nanoparticles on pharmacokinetic properties of the herb-derived active compounds or conventional chemical synthetic drugs has not yet been reviewed thoroughly. This systematic review aims to examine pharmacokinetic studies of nanoparticles loaded with herb-derived compounds and conventional chemotherapeutic drugs for cancer therapy.

Materials and methods {#S0002}
=====================

Study selection and inclusion and exclusion criteria {#S0002-S2001}
----------------------------------------------------

The systematic review was performed until February 2019 using PubMed and Science Direct databases. The search terms used were: "Pharmacokinetics", AND/OR "Pharmacokinetic study", AND "Nanoparticles", AND "Anticancer", AND/OR "Traditional medicine", AND/OR "Herbal medicine" AND/OR "Herb-derived compounds", AND/OR "Natural products", AND "Chemotherapy". The articles published from various journals were retrieved and saved in EndNote X8 for further analysis. The inclusion criteria were 1) full-text articles published in English, 2) In vitro or in vivo or clinical studies with application of nanoparticles of herb-derived compounds or conventional drugs for cancer chemotherapy, and 3) articles with in vivo/clinical pharmacokinetic studies reporting at least area under plasma concentration--time curve (AUC). All duplicates, review articles, articles with unclear methodology, or articles related to the application of nanoparticles in diagnostic/imaging, immunotherapy, radiotherapy, photothermal therapy, lipoprotein nanoparticles, gene therapy, hydrogel nanoparticles, conjugated ligands, and targeted therapy, as well as combined anticancer drugs were excluded from the analysis.

Data extraction and collection {#S0002-S2002}
------------------------------

The following study characteristics were extracted from each article that fulfilled the inclusion criteria and had none of the exclusion criteria: nanoparticles, drug-loaded, the analytical method applied, type of study, animal or human used, dose and route of loaded drugs given, and pharmacokinetic parameters (at least AUC). Final eligibility check of the full-text articles was performed; only articles that were relevant to the review question and keywords were obtained and processed for final analysis.

Results and discussion {#S0003}
======================

A total of 403 relevant research articles published up to February 2019 were retrieved from PubMed and Science Direct databases. All articles were imported and merged in EndNote reference management software. One hundred sixty-nine duplicate articles and 39 review articles were excluded. Of the remaining 195 articles, 167 articles were available as full-texts for eligibility screening. Finally, 50 articles fulfilling the inclusion criteria were included in the study ([Figure 2](#F0002){ref-type="fig"}). The pharmacokinetic studies of the nanoparticles of herb-derived compounds and conventional chemotherapeutic drugs for cancer are summarized in [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}.Table 1Summary of the in vivo/clinical pharmacokinetic studies of conventional chemotherapeutic drugs for cancer included in the analysis. Data are presented as mean values for nanoformulation vs free drugDrug-loadedNanoparticleAnimals used (n)/cell lineRoute, doseAnalytical techniquePharmacokinetic parameters (mean)OutcomesReferenceDaunorubicinCS--PLGA and PLGAWister rats (n=6)\
MCF-7 cell lineOral, 10 mg/kg bwUHPLC-MS/MSAUC~0--48~: 15,729, 8674.65 vs 1393 ng.hr/mL; C~**max**~: 591, 318.55 vs 44.65 ng/mL: T~max~: 4.00, 4.00 vs 2.00 hrs; t~1⁄2~: 152.7, 119.39 vs 54.55 hrs.Improved pharmacokinetics with CS-PLGA loaded drug than PLGA loaded drug with increased AUC (11.29-fold), C~max~ (1.86-fold), T~max~ (2-fold), and prolonged t~1/2~ (2.8-fold).\
Potential to avoid first pass metabolism with CYP450 and P-gp mediated efflux.[@CIT0022]LecithmerWistar rats (n=6) K562and Hop62celllinesIV, 4 mg/kg bwHPLCAUC: 31.2 vs 39.7 ng hr/mL; t**~1⁄2~**: 1.96 vs 1.63 hrs; Vd: 81.68 vs 57.46 L; CL: 28.87 vs 23.24 L/hrsThe only significantly improved pharmacokinetic was V~d~ (1.42-fold) with the rapid uptake of the reticuloendothelial system. Slightly Prolonged t~1/2~ (1.2-fold) decreased AUC (1.3-fold); Increased CL (1.24-fold)[@CIT0023]DocetaxelPHBVCharles Foster Rats (n=6).\
MCF-7 cell lineIV, 25 mg/kg bwHPLCAUC**~0-t~**: 914.9 vs 565 μg/mL\*hr; C~max~: 15.53 vs 41.06 μg/mL; T~max~: 72 vs 6 hrs; t~1~**~⁄2:~** 41.8 vs 5.09 hrs; CL: 0.019 vs 0.044 L/hr; V~ss~: 2.49 vs 0.171 L/hrsImproved pharmacokinetics: Increased AUC (1.6-fold); prolonged t~1/2~(8.2-fold); increased V~d~ (2.3-fold); decreased CL (2.3-fold)[@CIT0003]LCG-SNELS vs MCG-SNELSRats (n=3)\
Caco-2 cell lineOral, 20 mg/kg bwUPLCAUC: 9197.7, 7425.8 vs 847.2 ng·hr/mL; C~max~: 1597.2, 612.5 vs 346.9 ng/mL; T~max~: 1.42, 2.74 vs 3.27 hrsImproved pharmacokinetics: Increased AUC and C~max~ of LCG-SNELS loaded drug compared with MCH-SNELS loaded drug and free drug;\
LCG-SNELS: a preferred drug carrier than MCG-SNELS for better drug delivery to tumor cells.[@CIT0011]PS-PDLLAMale Sprague--Dawley (SD) rats (n=3).\
PC-3 cell lineIV, 1 mg/kg bw(LC-MS/MS)AUC: 23.56 vs 10.18 μg·min/mL; t**~1⁄2~**: 134.7 vs 57.8 mins; CL: 42.60 vs 99.03 mL/min/kg; V**~ss~**: 3260.9 vs 864.3 mL/kgImproved pharmacokinetics: Increased AUC (2.31-fold); prolonged t~1/2~ (2.33-fold); decreased CL (due to sustained release and stability of the drug in the serum).[@CIT0007]DocetaxelPoly (TMCC-co-LA)-g-PEGTumor (MDA-MB-231-H2N) bearing female mice (n=15).IV, 1.5 mg/kg bwUPLC-MSAUC**~0-8~**~hr~: 3.52×10^3^ vs 1.49 x 10^3^ hr.ng/mL; t~1~**~⁄2:~** 5.33 vs 3.32 h; Vd: 2.17×10^3^ vs 4.59×10^3^ mL/kg; CL: 282 vs 958 mL/hr/kgImproved pharmacokinetics: Decreased V~d~ (2-fold); prolonged t~1/2~ (1.6-fold); increased AUC~0-8h~ (2-fold); decreased CL (3-fold)[@CIT0010]PLA-TPGS Vs PLGAMale Sprague--Dawley (SD) rats (n=4)IV, 10 mg/kg bwHPLCAUC**~0-72~**~hr~: 49.9, 28.0 vs 23.4 mg/L\*hr; C~max:~ 11.0, 10.2 vs 15.9 mg/L; T~max~: 0.5, 0.5 vs 0.5 hr; t~1⁄2~: 27.9, 4.4 vs 2.1 hrs; V~d~: 7.8, 1.6 vs 1.4 L/kg; CL:0.2, 0.3 vs 0.4 L/hr/kgImproved pharmacokinetics of PLA-TPGS:\
Increased AUC~0-72h~ (2.13-fold); prolonged t~1/2~ (13.2-fold); decreased CL; increased Vd[@CIT0012]PLGA--PEG Vs PLGAfemale BALB/c mice (n=4)IV, 5 mg/kg bwMass spectrometerAUC: 9221, 6601 vs 1688±373 ng.h/mL; t~1⁄2~: 15.87, 6.05 vs 4.30 hrs; V~d~: 290.41, 150.81 vs 383.57 mL;\
CL: 12.54, 17.23 vs 61.79 mL/hrsImproved pharmacokinetics of PLGA-PEG-loaded drug compared with free drug solution and PLGA-loaded drug: Prolonged t~1/2~ (3.7-fold); increased AUC (5.4-fold); decreased CL (5-fold); decreased V~d~ (1.3-fold)\
PEG contributed extended circulation and sustained drug delivery.[@CIT0002]Thiolated chitosanWistar rats (n=5)\
Caco-2 cellsOral, 10 mg/kg bwHPLC analysisAUC: 44,998 vs 4243 ng.hr/mL; C~max~: 341 vs 456 ng/mL; T~max~: 5 vs 2 hrs; t**~1⁄2~**:102.5 vs 11.7 hrsImproved pharmacokinetics: Increased oral F, sustained release; Prolonged t~1/2~ .\
The improvement of pharmacokinetics could be related to muco-adhesion properties, P-gp efflux inhibition, and permeability-enhancing effects of thiolated chitosan.[@CIT0006]PLGA--mPEGTumor (C26 colon carcinoma) bearing mice (n=6).\
MCF-7 breast and C26 colon cancer cellsIV, 15 mg/kg bwHPLCAUC: (101.0 vs 36.8) μg.hr/mL; C~max~: 16.3 vs 17.5 μg/mL)**;** t**~1⁄2~**:7.26 vs 1.93 hrs; CL: 148.4 vs 407.1 mL/hr/kgImproved pharmacokinetics: increased AUC (2.7-fold), prolonged t~1/2~ (3.76-fold), and lowered CL (2.7-fold).\
Sustained release with increased accumulation in tumor cells and enhanced cytotoxicity against colon cancer.[@CIT0013]DocetaxelCMS-PEGTumor bearing BALB/c mice (n=3)\
LL/2 lung and EMT-6 mammary carcinoma cell lines.IV, 40 mg/kg bwLC/MSAUC: 881 vs 22.8 µg.hr/mL; C~max~: 27.4 vs 1.6 µg/mL; t**~1⁄2~**: 53.8 vs 10.3 hrs; CL: 43.9 vs 1752 mL/hr/kg; V**~d~**: 3418 vs 25,957 mL/kgImproved pharmacokinetics: Increased AUC (38.6-fold); prolonged t~1/2~ (5.2-fold); decreased CL (2.5%); decreased V~d~ (13.2%).\
Improved cytotoxic efficacy and cellular uptake of the loaded drug in tumor cells.[@CIT0009]PALA micellesMale Sprague--Dawley (SD) rats (n=6)\
human\
MCF-7 breast cell line.IV, 2.5 mg/kg bwHPLCAUC**~0--12~**: 2.67 vs 1.763 μg.hr/mL; t~**1⁄2**~: 1.16 vs 0.76 hrs; C~L~: 0.849 vs 1.151 L/hr/kgImproved pharmacokinetics: Prolonged t~1/2~ (1.53-fold); increased AUC (1.51-fold).\
Increased cytotoxicity against human MCF-7 breast cancer.[@CIT0005]DoxorubicinCHGCMale Sprague--Dawley rats (n=6)IV, 2 mg/kg bwHPLCAUC: 4.403 vs 0.666 mg.hr/L; CL: 0.454 vs 3.005 L/hr/kgImproved pharmacokinetics: Increased AUC (6.61-fold); decreased CL.\
Improved pharmacokinetics is due to slow release of the drug from nanoparticle.[@CIT0020]PAD--PPITumor-inducing albino rats (n=4)\
Lung cancer cell (A549)IV, 5 mg/kg bwHPLCAUC: 35.53 vs 11.23 mg. hr/mL; T~max~: 7.27 vs 1.49 hrs; CL: 140.726 vs 444.278 mg hr/mLImproved pharmacokinetics: Increased AUC (3.2-fold); decreased CL (3.12-fold).\
Improved cytotoxic effect of drug against cancer cell.[@CIT0021]PLGASprague--Dawley rats (n=3)Oral, 10 mg/kg bwHPLCAUC: 5282 vs 1452 ng.hr/mL; C~max~: 154.08 vs 64.68 ng/mL; T~max~: 36 vs 6 hrsImproved pharmacokinetics: Increased F and C~max~; prolonged t~1/2~[@CIT0016]mPEG-b-PCLMale Sprague--Dawley rats (n=4)\
MCF-7 and MCF-7/ADR cellsIV, 5 mg/kg bwMass spectrometryAUC~0--24~: 2268.426 vs 379.92 μg.hr/L; C~max~: 3617.1 vs 1704.6 mg/L; t~1⁄~**~2~**:1.95 vs 0.4 hrs; V~d~: 0.006 vs 0.009±0.006 L/kg; CL: 0.002 vs 0.013 L/hr/kgImproved pharmacokinetics: Increased AUC (5.97-fold); prolonged t~1/2~ (4.54-fold).\
Significantly increased cytotoxicity and reduced resistance in MCF-7/ADR cells[@CIT0014]DoxorubicinCS-g-TPGSFemale Sprague−Dawley rats (n=4)\
HepG2, BEL-7402, MCF-7, BEL-7402/5-Fu, and MCF-7/DOX cellsOral, 10 mg/kg bwHPLCAUC: 3.439 vs 1.459 mg.hr/L; C~max~: 0.451 vs 0.390 μg.hr/mL; T~max~: 2 vs 2 hrs; t~1⁄2~: 10.93 vs 4.33 hrs; CL: 2.899 vs 6.856 L/hr/kgImproved pharmacokinetics: **I**ncreased AUC (2.36-fold); prolonged t~1/2~ (2.53-fold); decreased CL.\
Chitosan (CT) nanoparticles shown as suitable carrier in drug-resistant cancer cells and increased cytotoxicity**.**[@CIT0015]Mannosylated- SLNsTumor bearing Male Balb/c mice (n=3)\
A549 and MCF-7 cell linesIV, 5 mgkg bwHPLCAUC: 55.99 vs 11.31 µg.hr/mL; C~max~: 4.0 vs 5.01 µg/mL; t~1⁄2~:14.53 vs 1.56 hrs; CL: 8.01 vs 43.03 mL/hrImproved pharmacokinetics: Increased AUC (5-fold); prolonged t~1/2~ (9.3-fold); decreased CL[@CIT0017]CSD-PEGMale Sprague--Dawley (SD) rats (n=3).\
SKOV-3 cellsIV, 4 mg/kg bwHPLCAUC: 234.42 vs 96.05 μg·min/mL; t~1⁄2~: 327.86 vs 60.09 mins; C~L~: 17.35 vs 41.95±4.22 mL/min/kg; V~ss~: 3153.22 vs 1105.95 mL/kg.Improved pharmacokinetics: Prolonged t~1/2~; increased AUC; decreased CL.\
Promising anticancer activity.[@CIT0019]NanodiskWistar rats (n=6)\
MCF-7 and P-gp overexpressing MCF-7/Adr cellsIV, 5 mg/kg bwUPLC−MS−MSAUC: 17,452.5 vs 550.8 μg·hr/L; t~1⁄2~: 41.9 vs 3.5 hrsImproved pharmacokinetics: Prolonged t~1/2~ (11.7-fold); increased AUC (31.7-fold).\
Increased cytotoxicity activity against tumor resistant cells (MCF-7/Adr cells).[@CIT0018]Estrone (ESC8)SLN\
NLC\
LiposomeSprague--Dawley rats (n=3)\
MDA-MB-231 (HTB-26), MDA-MB-468 (HTB-132), BT-474 (HTB-20), and SK-BR-3 (HTB-30)Oral, 20 mg/kg bwHPLCAUC: 17,728.97, 16,047.25, 8991.76 vs 12,357.10 μg.hr/mL; C~max~: 890.62, 792.53, 486.53 vs 534.70 μg/mL; T~max~: 7.32, 7.45, 6.80 vs 8.50 hrs; **t~1⁄2~**: 5.08, 5.16, 4.71 vs 5.89 hrs; V~d~: 2.07, 2.32, 3.78 vs 8.60 mL; CL: 0.28, 0.31, 0.56 vs 1.01 L/hrImproved pharmacokinetics: SLN and NLC increased AUC, decreased both CL and V~d~.\
Improved cytotoxicity activity of **s**olid lipid-loaded estrone against triple negative and nontriple negative breast cancer cell lines compared to NLC, liposome nanoparticles and free drug.[@CIT0030]5-Fluorouracil (5-FU)PEG-PBLGRabbit.\
Human colon (LoVo) and oral squamous (Tca8113) carcinoma cellsIV, 30 mg/kg bwHPLCAUC: 5794.7 vs 6263.8 μg.hr/L; C~max~: 4563.5 vs 17,047.3 μg/L; T~max~: 1.25 vs 0 hr; t~**1⁄2**~: 33.3 vs 0.088 hr; Vd: 0.114 vs 0.069 LProlonged t~1/2~; increased distribution time; decreased (slightly) AUC.\
Significantly improved antitumor activity against colon and oral cancer cells.[@CIT0024]GemcitabinemPEG-PLGA co-polymerBalb-c mice (n=4)\
MiaPaCa-2 and MCF-7 carcinoma cell linesIV, 2 mg/kg bwLC-MSAUC: 312.5, 209.5 vs 96.6 ng·hr/mL; t~1⁄2~: 3.8, 0.4 vs 0.2 hr; CL: 6400.3, 9545.8 vs 20,709.3 mL/hr/kgImproved pharmacokinetics of PEGylated PLGA loaded drug compared to non-PEGylated PLGA NPs loaded drug and free drug: Increased AUC; prolonged t~1/2~ (slightly)**;** decreased CL.\
Increased cytotoxicity against MiaPaCa-2 and MCF-7 cancer cell lines.[@CIT0028]Methotrexate (MTX)Glycine-PLGAWistar rats (n=3)\
MDA-MB-231 cellsIV, 5 mg/kg bwRP-HPLCAUC: 130.1 (30.9) μg.hr/mL; V~d~: 0.52 (0.65) L; t~1⁄2~: 4.30 (2.47) hrsImproved pharmacokinetics: Increased AUC (4-fold); Prolonged t~1/2~ (2-fold); decreased V~d~ (1-fold)\
Substantial increase of cytotoxicity against cancer cells.[@CIT0026]Mifepristone (MIF)CSMale rats (n=4)\
A549, Hela, RL95-2 and HepG2 cancer cellsOral, 30 mg/kg bwLC-MS/MSAUC**~0-24~**: 6.3 vs 2.0 mg.hr/L; C~max~: 0.79 vs 0.36 mg/L; T~max~: 5.0 vs 3.4 hrs; t~**1⁄2**~: 4.0 vs 3.0 hrsImproved pharmacokinetics: Improved AUC and C~max~, prolonged t~1/2~.\
Chitosan improved cytotoxicity of MIF against cancer cells.[@CIT0027]Noscapine (NOS)PCL-PEGWistar rats (n=3).\
MCF-7 cell lineIV, 50 mg/kg bwHPLCAUC: 9351.74 vs 7308.96 ng.hr/mL; C~max~: 2055.97 vs 3642.28 ng/mL; t~1⁄2~: 22.92 vs 5.12 hrsImproved pharmacokinetics: Increased AUC; prolonged t~1/2~ (4.47-fold); increased F.\
Improve cytotoxicity against breast cancer cells[@CIT0031]OxaliplatinFESNSMale Sprague-Dawley (SD) rats (n=6)Oral, 10 mg/kg bwHPLCAUC: 22,280.4, 17, 585.2 vs 3733.9 ng.hr/mL; C~max~: 8621.8, 4653.0 vs 304.6 ng/mL; T~max~: 1.3, 1.7 vs 1.9 hrsImproved pharmacokinetics: Increased AUC (4--6 fold); increased F[@CIT0025]PaclitaxelPEG2000, PEG6000, PEG10000Male Wistar rats (n=6)Oral, 10 mg/kg bwHPLCAUC: 56, 32, 13 vs 81 µg.hr/mL; C~max~: 2.1, 1.9, 1.4 vs 204 µg/mL; T~max~: 5.8, 3.0, 3.3 vs 0.01 hr; t~1⁄2~: 9.3, 6.2, 29 vs 2.6 hrsPEGylation of nanoparticles with either PEG6000 or PEG2000 as carriers were more adhesive in the GI mucosal than nanoparticles PEGylated with 1000 as they were located at the surface of the absorptive membrane for a long period, and slowly release the loaded drug.[@CIT0004]TPGS-PLGASprague--Dawley rats (n=3)\
C6 glioma cellsIV, 10 mg/kg bwLC/MS/MSAUC: 27,200 vs 35,470 ng.hr/mL; t**~1⁄2~**: 16.8 vs 0.830 hrsDecreased AUC (slightly); prolonged t~1/2~ (20-fold)\
Greater cytotoxicity activity against C6 glioma cells.[@CIT0001]PCL--TPGSWistar rats (n=5)\
MCF-7 and MDA-MB 231 human breast cancer cell linesIV, 6 mg/kg bwHPLCAUC: 7.07 vs 2.62 μg.hr/mL; t~1⁄2~: 10.13 vs 0.87 hrs; CL: 15.86 vs 49.15 mL/min; V~ss~: 8.89 vs 2.13 LImproved pharmacokinetics: Increased AUC (2.7-fold); prolonged t~1/2~ (11.6-fold);\
Decreased CL (3-fold)\
Improved anticancer activity against breast cancer cells.[@CIT0008]SirolimusmPEG--PLAMale Sprague-Dawley (SD) rats (n=3)\
A549, MCF7, NCI-H460 and MDA-MB-231 cellsIV, 10 mg/kg bwLC-MS/MSAUC: 16,901.7 vs 5366.7 µg.hr/mL; C~max~: 11,303.3 vs 2890 µg/mL; T~max~: 0.25 vs 0.25 hrsImproved pharmacokinetics: Increased AUC (3.15-fold) and C~max~ (3.91- fold).\
High cytotoxic activity against human cancer cells.[@CIT0032]Temozolomide (TMZ)PAMAM-CTWistar rats (n=6)\
U-251 and T-98G cellsIP, 3 mg/kg bwUV-Visible SpectrophotometerAUC: 4643.94 vs 3820.77 μg.hr/mL; Vd: 0.041 vs 0.0373 L/kg; t**~1⁄2~**:22.74 vs 15.348 hrs; CL: 0.00125 vs 0.00168 L/hr/kgImproved pharmacokinetics: Increased AUC (1.2-fold); prolonged t~1/2~ (1.5-fold).\
Improved cytotoxic potential against cancer cells.[@CIT0033]AnastrozolePLGA, PLA and PCLWistar rats (n=6)\
breast cancer cell lines (BT-549 and MCF-7)IV, 1 mg/kg bwHPLCAUC: 100.2, 405.7, 416.2 vs 21.0 μg.hr/mL; C~max~: 1.2, 2.0, 4.6 vs 8.3 μg/mL; t**~1⁄2~**: 196.12, 322.32, 293.19 vs 9.08 hrs; V~d~: 2.8, 1.146, 1.01 vs 0.623 L/kg; CL: 0.009, 0.0024, 0.0023 vs 0.0475 L/hr/kgImproved pharmacokinetics: Increased AUC (4.77, 19.31, and 19.81-fold, respectively); prolonged t~1/2~.\
Dose dependent cytotoxicity activity against breast cancer cells.[@CIT0029][^1] Table 2Summary of the in vivo/clinical pharmacokinetic studies of the nanoparticles of herb-derived compounds for cancer included in the analysis. Data are presented as mean values for nanoformulation vs free compoundDrug-loadedNanoparticleAnimal used (number)/cell lineRoute, doseAnalytical techniquePharmacokinetic parameters (mean)OutcomesReferenceα -Tocopherol succinate (α -TOS)NanoemulsionWistar male rats (n=6)\
MCF-7 cellsIP, 100 mg/kg bwHPLC.AUC: 1141.56 vs 637.98 mg.hr/mL; C~max~: 33.84 vs 19.40 mg/mL; T~max~: 5.00 vs 9.00 hrs; t**~1⁄2~**: 16.99 vs 7.82 hrs; CL: 0.10 vs 0.18 L/hrImproved pharmacokinetics: Increased C~max~(1.74-fold); increased AUC (1.79-fold); prolonged t~1/2~ (2.17-fold); decreased CL (slightly).\
Improved the anti-cancer activity against cancer cells.[@CIT0050]Topotecan (Topo)PLGASwiss albino mice (n=6)\
SKOV3 cellsIV, 10 mg/kg bwLC-MSAUC: 35,667.5 vs 7479.75 ng hr/mL; C~max~: 1326 vs 2100 ng/mL; T~max~: 3 vs 0.5 hrImproved pharmacokinetics: Increased F (13.05-fold).\
Enhanced cytotoxicity effect against cancer cells.[@CIT0042]Protopana-xadiol (PPD) Contain ginsenosides, derived from *Araliaceae*CubosomesMale rats (n=6)Oral, 2 mg/kg bwMass spectrometryAUC: 43.37 vs 25.76 mg.min/L; C~max~: 1004 vs 73.45 ng/mL; T~max~: 125 vs 85 mins; t**~1⁄2~**:372.59 vs 324.01 mins; CL: 0.068 vs 0.071 L/min/kgImproved oral bioavailability and prolonged t~1/2~ (slightly).[@CIT0045]Hydroxy-camptothecin (HCPT)PEG-PBLGNew Zealand rabbits (n=3)IV, 12 mg/kg bwHPLCAUC: 2175.9 vs 2459.0 µg.hr/L; C~max~: 1513.5 vs 2627.8 µg/L; T~max~: 1 vs 0 hr; t**~1⁄2~**:10.1 vs 4.5 hrs; V~d~: 20 vs 7.3 LImproved pharmacokinetics: Decreased C~max~ and AUC; increased V~d~; increased t~1/2.~[@CIT0041]10-Hydroxy-camptothecin (10-HCPT)NanocrystalsSprague--Dawley rats (n=10)IV, 5 mg/kg bwHPLCAUC: 4867.7 vs 1735.9 ng.hr/mL; CL: 10.65 vs 484.99 mL/hr; t~**1⁄2**~: 1.85 vs 0.62 hrsImproved pharmacokinetics: Increased AUC (2.98-fold); prolonged t~1/2~ (2.81-fold); decreased CL (45.5-fold).\
Effective drug delivery for HCPT.[@CIT0040]Genistein (Gen)mPEG-PCL/MCTsMale Sprague--Dawley rats (n=5)IV, 10 mg/kg bwUPLC-QTOF/MS**AUC~0-t~**: 8.48 vs 2.97 µM\*hr; **t~1⁄2~**: 9.96 vs 2.15 hrs;**CL**: 0.73 vs 2.94 L/hrs**Improved pharmacokinetics of Gen containing micellar emulsions as nanocarriers**: Increased AUC (4.6-fold); prolonged t~1/2~ (2.86-fold); decreased CL[@CIT0049]CurcuminPC-SNEDDSMale Sprague--Dawley rats (n=3).\
MDA-MB-231 breast cancer cell lineOral, 100 mg/kg bwLC-MS/MS**AUC**: 2196.9 vs 41.8 ng.hr/L; **C~max~**: 487.7 vs 21.6 ng/mL; T~max:~ 1.0 vs 1.0 hr; t~1⁄2~: 21.0 vs 4.1 hrs; CL: 46.0 vs 2421.7 L/hr/kg; V~d~: 144.5 vs 5607.3 L/kgImproved pharmacokinetics: Increased AUC (52-fold); prolongedt~1/2~ (5-fold); decreased CL (50-fold); decreased V~d~ (38.8-fold).[@CIT0034]Lipid nanocapsulesRats (n=3).\
Rat 9L glioma cellsIV, 10 mg/kg bwLC-MS/MSAUC: 72.98 vs 18.77 μg.hr/mL; C~max~: 70.05 vs 13.05 μg/mL; t~1⁄2~: 3.25 vs 1.15 hrs; CL: 0.04 vs 0.13 μg/mL/hrImproved pharmacokinetics: Increased AUC (3.9-fold) and C~max~ (5.3-fold); decreased CL.[@CIT0036]Cationic Copolymer (EE100)Albino Wistar rats (n=6)\
Colorectal cancer cells\
(Colon-26)Oral, 50 mg/kg bwHPLCAUC: 2199.116 vs 23.225 ng.hr/mL; C~max~: 870.3104 vs 9.582 ng/mL; T~max:~ 0.5 vs 0.5 hr; t~1⁄2~: 4.811 vs 1.25 hrsImproved pharmacokinetics: Increased oral bioavailability.\
Improved cytotoxicity against colorectal cancer cells.[@CIT0035]mPEG-PCLWistar rats (n=6).\
Hela and HT-29 cellsIV, 15 mg/kg bwHPLCAUC: 4464.601 vs 967.221 μg.hr/L; V~d~: 6.271 vs 4.432 L/kg; CL: 3.36 vs 15.508 L/hr/kg; t~1~**~⁄2~**:1.294 vs 0.198 hrsImproved pharmacokinetics: Increased AUC; prolonged t~1/2~; increased V~d~; decreased C~L~.[@CIT0038]PDLLA-GMale Sprague--Dawley (SD) rats (n=3).\
MDA-MB-231 cellsIV, 12 mg/kg bwLC--MS/MSAUC: 1810.09 vs 1.79 μg.min/mL; t~1⁄2~: 85.7 vs 6.62 h; C~L~: 6.87 vs 6817.94 mL/min/kg; V~ss~: 123.56 vs 62,061.86 mL/kgImproved pharmacokinetics: Increased AUC; prolonged t~1/2~.[@CIT0039]Curcumin and\
RutinChitosanRabbits (n=3)Oral, 35 mg eachRP-UFLCAUC: 4322.37, 1219.80, 7621.79 vs 1146.73 ng.h/mL; C~max~: 971.72, 317.97, 1113.55 vs 262.85 ng/mL; T~max~: 1 hr for all; **t~1⁄2~:** 2.62, 1.78, 3.357 vs 1.74 hrsImproved pharmacokinetics: Increased AUC of curcumin (3.5-fold) and rutin (6.65-fold); increased C~max~ of curcumin (3.06-fold) and rutin(4.24-fold).[@CIT0037]*Brucea javanica*oil (BJO) is from *Brucea javanica* of the family SimaroubaceaeCationic nanoemulsionMale Sprague--Dawley (SD) rats (n=6).\
Human lung adenocarcinoma line A549 cells xenografts in nude mice.Oral, 505 mg/kg bwUPLC-MS/MSAUC: 1203.4 vs 982.5 mg·hrs/L; C~max~: 210.2 vs 164.2 mg/L; T~max~: 3.5 vs 3.0 hrs; t~**1⁄2**~: 4.5 vs 3.3 hrsImproved pharmacokinetics: Increased AUC and t~1/2~ (1.6- and 1.3-fold, respectively).\
Reduced growth of lung cancer and decreased the frequency of dosing.[@CIT0048]Camptothecin (CPT)SLNBALB/c mice (n=4).\
Caco-2, HT-29, HepG2 and MCF-7 cell lines.Oral, 30 mg/kg bwHPLCAUC: 17.19 vs 7.22 μg.hr/L; C~max~: 3.28 vs 0.69 μg/mLImproved pharmacokinetics: Increased AUC and C~max~ (2.38- and 4.75-fold, respectively).\
Higher cytotoxicity against all four cell lines.[@CIT0043]*Celastrol* (CST)\
Isolated from *Trypterygium wilfordii hook*PhytosomesRabbits (n=6)Oral, 40 mg/kg bwHPLCAUC: 767.51 vs 186.84 ng.hr/mL; C~max~: 460 vs 92 ng/mL; T~max~: 0.5 vs 1 hr; t~**1⁄2**~: 10.1 vs 0.96 hrsImproved pharmacokinetics: Increased C~max~ and AUC; prolonged t~1/2~.\
The phospholipid component of phytosomes enhanced the fluidity of cell membrane, solubility, and intestinal absorption.[@CIT0047]Amoitone B\
Cytosporone B (Csn-B) analog, derived from *Dothiorella sp. HTF3.*NanocrystalsNew Zealand white rabbits (n=4)IV, 8.0 mg/kg bwHPLCAUC: 4.902 vs 3.439 mg.hr/L; t~1⁄2~: 8.446 vs 2.999 hrs; CL: 1.632 vs 2.327 L/hr/kg; V~d~: 0.626 vs 0.283 L/kgImproved pharmacokinetics: Increased AUC (1.4-fold); prolonged t~1/2~ (2.8-fold); decreased CL; increased V~d~ (slightly).[@CIT0044]*Biochanin A* (BCA)\
From red cloverPEG--NLCFemale Sprague--Dawley (SD) rats (n=6)\
Human breast cancer cell line (MCF-7)Oral, 4 mg/kg bwHPLCAUC: 590.01 vs 203.71 ng.hr/mL; C~max~: 165.82 vs 10.53 ng/mL; T~max~: 0.50 vs 0.33 hrImproved pharmacokinetics: Increased AUC (2.9-fold) and C~max~\
Increased cytotoxicity in MCF-7 cells.[@CIT0046][^2] Figure 2Flowchart summarizing inclusion and exclusion of the articles for the study.

Pharmacokinetic studies for nanoparticle-loaded chemotherapeutic drugs {#S0003-S2001}
----------------------------------------------------------------------

### Taxanes {#S0003-S2001-S3001}

Paclitaxel (PTX)[@CIT0001],[@CIT0004] and docetaxel (DTX)[@CIT0002],[@CIT0003],[@CIT0005],[@CIT0006] are semisynthetic anticancer drugs derived from the plants of the genus *Taxus* (yews). The anticancer activity of taxanes involves disruption of the mitotic spindle by binding to microtubules and thereby inhibiting the depolymerization of the microtubules, leading to mitotic arrest at the G2/M phase of the cell cycle.[@CIT0001]--[@CIT0004],[@CIT0006],[@CIT0007] PTX and DTX display anticancer activity and have been used in the treatment of various cancers especially breast,[@CIT0002]--[@CIT0004],[@CIT0006]--[@CIT0011] ovarian,[@CIT0001]--[@CIT0004],[@CIT0006]--[@CIT0008],[@CIT0011] lung,[@CIT0001]--[@CIT0004],[@CIT0006],[@CIT0007],[@CIT0009],[@CIT0011] head and neck,[@CIT0001],[@CIT0002],[@CIT0006],[@CIT0011] colon,[@CIT0001],[@CIT0004] bladder,[@CIT0001],[@CIT0002] prostate,[@CIT0002],[@CIT0007],[@CIT0011] and gastric[@CIT0002],[@CIT0003] cancers, esophageal, endometrium carcinoma,[@CIT0002] hepatocarcinoma,[@CIT0012] acute leukemia,[@CIT0001] and Kaposi's sarcoma.[@CIT0004] The clinical application of currently available taxanes meets some challenges including poor water solubility, high protein binding, first-pass metabolism, high affinity to P-glycoprotein (P-gp), and some serious side effects. The toxicity such as hypersensitivity, neuropathy, neurotoxicity, and cardiotoxicity is caused by the formulation excipients, ie, Tween 80, cremophor EL, and ethanol to increase its solubility. These excipients not only contribute to toxicity but also alter the pharmacokinetics of both drugs. One of the strategies proposed to address the problem of toxicity and poor pharmacokinetic properties with these drugs is the use of a novel drug delivery system such as nanoparticles. A wide range of biocompatible, biodegradable, and nontoxic polymeric nanoparticles were employed to improve the pharmacokinetic profiles of DTX and PTX to increase the plasma drug concentrations and solubility, and intracellular accumulation to tumors cells via enhanced permeability and retention (EPR) effect.[@CIT0001]--[@CIT0004],[@CIT0006]--[@CIT0009],[@CIT0011],[@CIT0012]

DTX encapsulated with pegylated carboxymethylcellulose (PEG-CMS) was evaluated against tumor-bearing Bagg Albino (BALB/c) mice at 40 mg/kg body weight injected via the tail vein. This nanoparticle provided improved pharmacokinetics of DTX (38-fold increase in AUC, 5.2-fold prolongation of t~1/2~, 2.5% decrease in CL, and 13.2% decrease in V~d~) compared with the free drug.[@CIT0009] This resulted in the increase of drug uptake to tumor cells in EMT-6 tumor-bearing mice with reduced toxicity. Similar findings were observed with poly (2-methyl, 2-carboxytrimethylene carbonate-co-D, L-lactide)-g-poly(ethylene glycol) (TMCCco-LA)-g-PEG nanoparticle delivering DTX, and free DTX. Improved drug plasma concentration in tumor-bearing mice was found with the increase of AUC (2-fold), prolongation of t~1/2~ (1.6-fold), and decrease of both Vd (2-fold) and CL (3-fold). These changes likely contributed to the favorable pharmacokinetic profile and tumor accumulation of DTX.[@CIT0010] Likewise, poly(lactide-co-glycolide)-monomethoxy-poly-(polyethylene glycol) (PLGA-mPEG)-loaded DTX was shown to provide sustained release of DTX and increase the accumulation of the drug in tumor cells of mice and thus, enhancement of cytotoxic activity.[@CIT0013] The change in the pharmacokinetics of DTX with increase of AUC (2.7-fold), prolongation of t~1/2~ (3.76-fold), and decrease of CL (2.7-fold) was brought by the addition of PEG to the PLGA nanoparticle which contributed to increased blood circulation, decreased drug-protein binding, and reduced elimination of loaded drug by reticuloendothelial system (RES) organs such as liver and spleen.

Formulations of DTX using PLA-TPGS, PS-PDLLA, and PALA polymeric nanoparticles were found to improve the pharmacokinetics of DTX in Sprague--Dawley (SD) rats.[@CIT0005],[@CIT0007],[@CIT0012] The AUC was increased (1.5-2.31-fold), and the t~1/2~ was prolonged (1.53-13.2-fold) with a significant reduction of drug CL. The improved bioavailability of PLA-TPGS nanoparticle-loaded DTX due to an inhibitory effect on P-gp resulted in enhancing cellular uptake of the drug to cancer cells and overcoming multidrug resistance. The decrease in clearance of the loaded drug was due to sustained release and stability of the drug in the serum. Another study evaluated the pharmacokinetics of PEGylated PLGA nanoparticle-loaded DTX in tumor-bearing mice. The pharmacokinetics of DTX was found to be improved with an increase in AUC (5.4-fold), prolongation of t~1/2~ (3.7-fold), and decrease of CL (5-fold) and V~d~ (1.3-fold).[@CIT0002]

Lipid-based nanocarriers such as self-nano emulsifying lipidic nanomicellar systems (SNELS) were also used to deliver DTX. Both long-chain and medium-chain glycerides were applied to enhance oral drug bioavailability.[@CIT0011] The nanocarriers of long-chain glycerides enriched with SNELS delivering DTX were shown to markedly increase the AUC and C~max~ of DTX compared with the medium-chain glyceride SNELS. The superiority of the long-chain carrier was mainly due to inhibition of P-gp efflux, together with the increase of intestinal lymphatic transport of drug with reduction of the first-pass metabolism. Finally, poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) delivering DTX was shown to improve the pharmacokinetics of DTX resulting in the increase of AUC (1.6-fold), the prolongation of t~1/2~ (8.2-fold), the expansion of V~d~ (2.3-fold), and the reduction of CL (2.3-fold).[@CIT0003] Similarly, DTX incorporated into thiolated chitosan provided higher oral drug bioavailability, sustained release, and longer t~1/2~ compared to the unloaded drug.[@CIT0006] The 10.6-fold increase of mean AUC of DTX when loaded with thiolated chitosan could be related to its muco-adhesion properties on the gastrointestinal tract.

In contrast to DTX, improvement of drug bioavailability was not demonstrated with PTX when encapsulated with PEG with different molecular weights (2000, 6000, and 10,000)[@CIT0004] and PLGA-TPGS,[@CIT0001] but t~1/2~ was mostly prolonged. PEGylation of nanoparticles with either PEG6000 or PEG2000 as carriers was more adhesive in the gastrointestinal mucosa than PEGy1000. Both were located at the surface of the absorptive membrane for an extended period, and the loaded drug was slowly released. When PTX was loaded with PCL-TPGS on the other hand, the AUC was increased by 2.7-fold, the t~1/2~ was significantly increased, while the CL was significantly decreased (3-fold).[@CIT0008]

### Anthracycline antibiotics {#S0003-S2001-S3002}

The anthracycline antibiotics doxorubicin (DOX) and daunorubicin (DNR) are broadly used for the treatment of a variety of cancers. They exert their action on cancer cells by intercalation into DNA base pairs resulting in blockage of DNA and RNA synthesis and DNA scission, which suppresses the replication of DNA and induces cell apoptosis.[@CIT0014] The pharmacokinetic study in male SD rats showed that entrapment of DOX in polymersomes resulted in the prolongation of drug t~1/2~ by 4.54-fold, and the increase in AUC by 5.97-fold compared with free drug. These pharmacokinetic changes significantly enhanced cytotoxicity and reduced resistance of MCF-7/ADR cells to DOX.[@CIT0014] An improved pharmacokinetic profile of DOX and its cytotoxicity were also reported when loaded in chitosan-g-TPGS (CT). This makes CT a suitable carrier in drug-resistant cancer cells.[@CIT0015] In another in vivo study using DOX loaded in PLGA administered to SD, the formulation provided relatively well-sustained plasma concentration, enhanced AUC, and significantly delayed T~max~ (36 hrs) when compared to free DTX.[@CIT0016] Furthermore, improved pharmacokinetics and antitumor activity of the mannosylated solid lipid nanoparticles delivering DOX were demonstrated in Balb/c mice compared with free drug. The approximately 9.31-fold increase of t~1/2~ and the 5-fold increase of AUC suggested that mannosylated solid lipid nanoparticles could selectively deliver DOX to tumor cells.[@CIT0017]

A nanodisk formulation of DOX was reported to provide larger AUC, longer t~1/2~, and higher cytotoxicity in MCF-7/ADR cells compared with free drug.[@CIT0018] Additionally, DOX encapsulated into the chondroitin sulfate A-deoxycholic acid-polyethylene glycol (CSD-PEG) also showed similar improvement in pharmacokinetics and stability of DOX in blood.[@CIT0019] Cholesterol-modified glycol chitosan (CHGC) delivering DOX improved F of about 6.61 times higher than the free drug. The improved pharmacokinetics could be due to the slow release of the drug from the nanoparticle, which contributed to higher uptake by the cancer cells.[@CIT0020] Dextran-conjugated with polypropylene imine (PAD-PPI) delivering DOX was reported to increase AUC and decrease CL by 3.2-fold and 3.12-fold, respectively, compared with free drug. This nanoparticle resulted in the improved cytotoxic effect of DOX to the tumor cells.[@CIT0021]

For DNR, the increase in C~max~ (1.86-fold), AUC (11.29-fold), T~max~ (2-fold), and prolongation of t½ (2.8-fold) compared with free MTX was reported in Wistar rats after oral administration of the drug incorporated with chitosan-poly(lactic-co-glycolic acid) (CS-PLGA) nanoparticle.[@CIT0022] This was due to the potential of the nanoparticle to avoid P-gp-mediated-drug efflux and hepatic first-pass metabolism by cytochrome P450 (CYP450) enzymes. On the other hand, improvement of the pharmacokinetics of DNR conjugated into lecithmer was not well demonstrated in Wistar rats.[@CIT0023] Drug-loaded nanoparticle exhibited an increase in V~d~ (1.42-fold) and a decrease in AUC (1.3-fold) compared with free drug. The larger V~d~ of DNR-loaded lecithmer was associated with rapid tissue distribution and uptake of the drug by the RES organs.

### Other anticancer drugs {#S0003-S2001-S3003}

5-Fluorouracil (5-FU), a pyrimidine analog for various types of solid tumors, is a prodrug which covalently binds to thymidylate synthase and interferes with thymidylate synthesis, resulting in inhibition of synthesis of both DNA and RNA. In rabbits, a dose of 30 mg/kg of 5-FU (30 mg/kg body weight) loaded into poly-ethylene glycol and poly (γ-benzyl-L-glutamate) (PEG-PBLG) was reported to result in lower F with slightly favorable t~1/2~ compared with the non-conjugated drug. The PEG-PBLG nanoparticle significantly improved antitumor activity against human colon and oral cancer cells.[@CIT0024]

The bioavailability of the platinum-based oxaliplatin (OLP) containing Fat Employing Supercritical Nano System (FESNS) as nanoparticle was shown to be improved compared with free OLP formulation.[@CIT0025] Furthermore, improvement in the pharmacokinetic profile of methotrexate (MTX) was reported when loaded in glycine-PLGA nanoparticle with an increase in AUC (4-fold), the prolongation of t~1/2~ (1.74-fold), and the reduction of V~d~ (1-fold).[@CIT0026] The nanoparticle substantially increased the cytotoxicity of MTX against MDA-MB-231 cancer cells. Different nanoparticles were shown to improve pharmacokinetics, particularly oral bioavailability of mifepristone, gemcitabine, anastrozole, and estrone. Improved bioavailability and cytotoxicity against cancer cells of mifepristone were shown when encapsulated with chitosan.[@CIT0027] Improved bioavailability, reduced CL, and prolonged t~1/2~ were reported with PLGA nanoparticle-loaded gemcitabine, resulting in enhanced cytotoxicity against MiaPaCa-2 and MCF-7 cells.[@CIT0028] The pharmacokinetic profiles and cytotoxic activity of anastrozole, the aromatase inhibitor used in postmenopausal breast cancer, were shown to be significantly improved when encapsulated in PLGA, PLA, and PCL polymers.[@CIT0029] Estrone was formulated with solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and liposomes. Mean AUC values of the drug were greatly increased with SLN (17,728 μg/mL\*h^2^) and NLC (16,047 μg/mL\*h^2^), but slightly decreased with liposomes (8991 μg/mL\*h^2^) compared with free estrone (12,357 μg/mL\*h^2^). Both CL and V~d~ were decreased. SLN emerges as a promising carrier of estrone to cancer cells.[@CIT0030] Noscapine, a derivative of alkaloid opium with anti-tubulin action, is currently under investigation for cancer. Poly(ethylene glycol)-co-poly(ε-caprolactone) (PCL-PEG) nanoparticle delivering noscapine was evaluated in Wistar rats, and drug bioavailability and t~1/2~ were shown to be increased along with the improvement of cytotoxicity against breast cancer cells.[@CIT0031] The pharmacokinetic profile of polymeric nanoparticle containing polyethylene glycol-poly-l-lactic acid (mPEG--PLA) delivering sirolimus, an mTOR inhibitor, was significantly improved with the increase of AUC (3-fold) and C~max~ (3.91-fold) compared with free sirolimus.[@CIT0032] The nanoparticle improved the cytotoxic activity of sirolimus against human cancer cell lines. In another study of polyamidoamine-chitosan (PCT) carrying temozolomide, promising pharmacokinetic profiles were reported with improved AUC (1.2-fold) and prolonged t~1/2~ (1.5-fold) compared with free drug.[@CIT0033]

Pharmacokinetic studies for nanoparticles loaded herb-derived compounds in traditional or herbal medicines {#S0003-S2002}
----------------------------------------------------------------------------------------------------------

Various nanoparticles were developed for the selective delivery of active compounds from traditional or herbal medicines to cancer cells. Curcumin, a molecule found in various spices, notably turmeric, has been used for the treatment of various types of cancer particularly breast, stomach, intestine, colorectal, prostate, ovarian, and melanoma.[@CIT0034],[@CIT0035] Curcumin exerts its anticancer activity by regulating signaling pathways such as Akt/mTOR, NF-κB, and HIF-1α which are important for cell proliferation and apoptosis.[@CIT0034],[@CIT0036] Compared with free drug, the AUC and t~1/2~ of curcumin-loaded in phospholipid complex in self-nano-emulsifying drug delivery system (SNEDDS) were increased by 52-fold and 5-fold, respectively. The V~d~ and CL were decreased by 38.8-fold and 50-fold, respectively. The improved oral bioavailability of curcumin resulted in improved luminal solubility. The higher release rate in the intestinal fluids improved absorption by enhancing compound permeability and avoiding hepatic first-pass metabolism.[@CIT0034] The significant improvement in the oral bioavailability of curcumin was reported when encapsulated into cationic polymer EE100 with increased cytotoxic activity against colorectal cancer.[@CIT0035]

The mean AUC values of chitosan-loaded curcumin, chitosan-loaded rutin, free curcumin, and free rutin were 4322, 7621, 1219, and 1146 ng/mL, respectively. Chitosan nanoparticle loading resulted in the improvement of bioavailability of curcumin and rutin by 3.5-fold and 6.65-fold, respectively, compared with free compounds.[@CIT0037] Similarly, another study in rats showed that lipid nanocapsules (LNC) efficiently delivered curcumin into tumor cells and improved its pharmacokinetics.[@CIT0036] The AUC and C~max~ were increased by 3.9-fold and 5.3-fold, respectively, while the CL was decreased by 3-fold. These results suggested that LNC could be used for the delivery of traditional medicines to cancer cells. The methoxy poly(ethylene glycol)-b-poly(ε-caprolactone) (mPEG-PCL) micelles could extend the plasma concentration and delay the clearance of curcumin.[@CIT0038] The bioavailability and t~1/2~ of curcumin were greatly improved when loaded with Poly (D, L-lactic acid)-glycerol (PDLLA-G) when compared with free curcumin.[@CIT0039]

Camptothecins constitute a class of anticancer alkaloid traditionally from Chinese medicine that possesses potential anticancer activity against colon, breast, colorectal, stomach, liver, leukemia, and ovarian cancers. Their mechanism of action involves inhibition of tumor-specific topoisomerase I, a critical enzyme responsible for cutting and re-ligating single DNA strands, which results in DNA damage.[@CIT0040]--[@CIT0043] The pharmacokinetic profile and anticancer activity of nanocrystals and PEG-PBLG loaded into hydroxycamptothecin (HCPT) were evaluated in rats and rabbits.[@CIT0040],[@CIT0041] Nanocrystals improved the pharmacokinetics of HCPT with an increase of AUC (2.98-fold), the prolongation of t~1/2~ (2.81-fold), and the decrease of V~d~ (45.5-fold) compared with free HCPT. The nanocrystals emerged as an effective drug delivery system for HCPT.[@CIT0040] On the other hand, another study in rabbits reported a decrease in C~max~ and bioavailability of HCPT when loaded in PEG-PBLG compared with free drug. The nanoparticle provided sustained release and prolongation of t~1/2~.[@CIT0041] Topotecan, a topoisomerase inhibitor which is a synthetic analog of camptothecin, was shown to enhance intracellular uptake and result in a 13-fold increase in bioavailability of topotecan-loaded PLGA compared with free topotecan.[@CIT0042] The increased bioavailability was associated with enhanced cytotoxic activity against SKOV3 cancer cells. Similarly, the bioavailability of the solid lipid nanoparticles (SLN) delivering camptothecin (CPT) was shown to be improved by 2.38-fold.[@CIT0043]

Amoitone B is a cytosporone B (Csn-B) analog obtained from *Dothiorella sp. HTF3*. It exhibits anticancer activity by tightly binding to a nuclear orphan receptor (Nur77) and induces mitochondrial apoptosis. When Amoitone B was loaded into nanocrystals (NC-Am), the bioavailability was increased by 1.4-fold and the t~1/2~ was prolonged by 2.8-fold. The nanocrystals improved solubility and reduced toxicity of Amoitone B.[@CIT0044] Further, cubic nanoparticles improved oral bioavailability and anticancer activity of protopanaxadiol (PPD).[@CIT0045] PPD which contains ginsenosides derived from the *Araliaceae* family was proved to exhibit potential anticancer activity. In another study, biochanin A (BCA), the compound from a phytoestrogenic plant of red clover, was found to exhibit estrogenic activity and cytotoxic activity against human breast cancer cells. The bioavailability of PEG-NLC-loaded BCA was increased by about 2.9-fold after oral administration to rats compared with BCA suspension. This subsequently improved the cytotoxic activity of BCA against MCF-7 cells.[@CIT0046] The bioavailability of celastrol was increased by 4.11-fold, and the t~1/2~ was prolonged by 10-fold when loaded with phytosomes compared with celastrol suspension.[@CIT0047] This suggested that the phospholipid component of phytosomes enhanced the fluidity of cell membrane, solubility, and intestinal absorption.

Cationic nanoemulsions (CN) containing chitosan delivering Brucea*javanica*oil (BJO) resulted in higher cytotoxicity and antitumor activity in a xenografted mouse model (A549 cells). The AUC of BJO-CN was increased by 1.6-fold, and the t~1/2~ was prolonged by 1.3-fold compared with BJO emulsion. CN has been demonstrated as a promising drug delivery system and has the potential to reduce the required frequency of BJO dosing.[@CIT0048] Genistein (Gen), an active compound found in soybeans, exerted its anticancer activity by inducing apoptosis through inhibiting tyrosine kinases and NF-κB. Micellar emulsions containing methoxy poly (ethylene glycol)-block-(ε-caprolactone) and medium-chain triglycerides (mPEG -PCL/MCTs) as nanocarriers delivering Gen prolonged t~1/2~ (2.86-fold) reduced CL (10.13-fold) and improved AUC (4.6-fold).[@CIT0049] Similarly, α-tocopherol succinate-loaded in nano-emulsion increased AUC (2.17-fold) and prolonged t~1/2~ (2.17-fold) compared with free α --TOS.[@CIT0050] The nano-emulsion proved to be a promising drug delivery system for cancer cells.

Conclusion {#S0004}
==========

It is evident that the pharmacokinetic profiles of conventional chemotherapeutic drugs as well as traditional/herbal medicines used for cancer treatment are significantly improved when loaded with nanoparticles. The main benefits of using nanoparticles for drug delivery are enhancement of vascular and gastrointestinal permeability and selectivity of drugs/compound to tumor cells. The improved permeability and selectivity resulted in the improvement of cellular drug uptake, the inhibition of drug hepatic first-pass metabolism and P-gp efflux, the increase in drug solubility and stability, and the decrease in the rate of drug elimination by the RES organs. Subsequent reduction of dose frequency further contributes to the improvement of patient compliance and minimizes toxicity. It is noted however that the physicochemical properties of the chemotherapeutic drugs or herb-derived compounds play a crucial rule in designing effective and appropriate nanocarriers. The use of nanoparticles as a novel drug delivery system for cancer therapy has the potential to dramatically improve both pharmacokinetics and cytotoxicity activity of the loaded drugs/herb-derived compounds for cancer therapy.
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MCF-7/ADR, Michigan Cancer Foundation-7-Adriamycin resistant; MDA-MB-231, M.D. Anderson-Metastasis Breast cancer; Akt/mTOR, protein kinase B/mammalian target of rapamycin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; HIF-1α, Hypoxia-inducible factor 1-alpha.
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[^1]: **Abbreviations:** Nano carriers: CHGC, cholesterol-modified glycol chitosan; CMS-PEG, PEGylated carboxymethyl cellulose; CS, chitosan; CSD-PEG, chondroitin sulfate A-deoxycholic acid-polyethylene glycol; CS-g-TPGS, chitosan-D-α-tocopheryl polyethylene glycol succinate; CS-PLGA, chitosan-poly(lactic-co-glycolic acid); FESNS, fat employing supercritical nano system; LCG-SNELS, long-chain glyceride-self-nanoemulsifying lipidic nanomicelles systems; MCG-SNELS, medium-chain glyceride-self-nanoemulsifying lipidic nanomicelles systems; mPEG-b-PCL, methoxy poly(ethylene glycol)-b-poly(ε-caprolactone); mPEG-PLA, methoxy poly(ethylene glycol)-*b-* poly(lactic acid); mPEG-PLGA, methoxy poly(ethylene glycol)-*b-* poly (lactic-co-glycolic acid); NLC, nanostructured lipid carriers; PAD-PPI, polyaldehydodextran-polypropylene imine; PALA, poly(d,L-lactic acid); PAMAM-CT, polyamidoamine-chitosan; PCL, poly(ε-caprolactone); PCL-PEG, polyethylene glycol-co-poly(ε-caprolactone); PCL-TPGS, Polyethylene glycol-co-D-α-tocopheryl polyethylene glycol succinate; PEG, polyethylene glycol; PEG10000, polyethylene glycol molecular weight 10,000; PEG2000, polyethylene glycol molecular weight 2000; PEG6000, polyethylene glycol molecular weight 6000; PEG-PBLG, poly(ethylene glycol) and poly(γ-benzyl-L-glutamate); PHBV, polyhydroxybutyrate-co-hydroxyvalerate; PLA,poly(lactic acid); PLA-TPGS, poly(lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate; PLGA, poly (lactic-co-glycolic acid); PLGA-mPEG, poly(lactic-co-glycolic acid)-b-methoxy poly(ethylene glycol); PLGA-PEG, poly(lactic-co-glycolic acid)-poly(ethylene glycol); Poly(TMCC-co-LA)-g-PEG, poly(2-methyl-2-carboxytrimethylene carbonate-co-D,L-lactide)-graft-poly(ethylene glycol); PS-PDLLA, poly (styrene)-b-poly(DL-lactide); SLN, solid lipid nanoparticles; TPGS-PLGA, D-α-tocopheryl polyethylene glycol succinate-poly(lactic-co-glycolic acid). Pharmacokinetic parameters: AUC, area under plasma concentration--time profile; C~max~, maximum plasma concentration; CL, total clearance; F, bioavailability; t~max~, time to maximum plasma concentration; t~1/2~, elimination half-life; V~d~, apparent volume of distribution; V~ss~, volume of distribution at steady-state.

[^2]: **Abbreviations:** Nanocarriers: mPEG-PCL/MCTs, methoxy poly(ethylene glycol)-b-poly(ε-caprolactone) and medium-chain triglycerides; mPEG-PCL, methoxy poly(ethylene glycol)-b-poly(ε -caprolactone); PCL, poly(ε-caprolactone); PC-SNEDDS, phospholipid complexes and self-nano-emulsifying drug delivery system; PDLLA-G, poly(D,L-lactic acid)-glycerol; PDLLA-G, poly(D,L-lactic acid)-glycerol; PEG-NLC, poly(ethylene glycol)-nanostructured lipid carriers; PEG-PBLG, poly(ethylene-glycol)-poly(gamma-benzyl-L-glutamate); PLA, poly(lactic acid); PLGA, poly(lactic-co-glycolic acid); SLN, solid lipid nanoparticles. Pharmacokinetic parameters: AUC, area under plasma concentration--time profile; C~max~, maximum plasma concentration; CL, total clearance; F, bioavailability; t~max~, time to maximum plasma concentration; t~1/2~, elimination half-life; V~d~, apparent volume of distribution; V~ss~, volume of distribution at steady-state.
